BioCentury | Nov 9, 2015
Clinical News

Yondelis trabectedin regulatory update

...Janssen has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Oct 19, 2015
Clinical News

Yondelis trabectedin regulatory update

...alkaloid that binds the minor groove of DNA in Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Oct 12, 2015
Clinical News

Bamosiran: Phase II data

...a baseline IOP of >=25 mmHg. Bamosiran was well tolerated. Sylentis is a subsidiary of Zeltia S.A....
BioCentury | Oct 12, 2015
Clinical News

Yondelis trabectedin: Updated Phase III data

...unit has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Sep 28, 2015
Clinical News

Lurbinectedin: Phase II started

...Ewing’s family of tumors and carcinoma of unknown primary site. PharmaMar is a subsidiary of Zeltia S.A....
BioCentury | Sep 28, 2015
Clinical News

Yondelis trabectedin: Phase II started

...Johnson has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Sep 21, 2015
Clinical News

Yondelis trabectedin: Additional Phase II data

...unit has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Jul 13, 2015
Clinical News

Lurbinectedin: Phase III started

...vs. pegylated liposomal doxorubicin or topotecan in about 420 patients. PharmaMar is a subsidiary of Zeltia S.A....
BioCentury | Jun 22, 2015
Clinical News

Lurbinectedin: Phase Ib data

...at the American Society of Clinical Oncology meeting in Chicago. PharmaMar is a subsidiary of Zeltia S.A....
BioCentury | Jun 22, 2015
Clinical News

Yondelis trabectedin: Interim Phase III data

...Janssen has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
Items per page:
1 - 10 of 171
BioCentury | Nov 9, 2015
Clinical News

Yondelis trabectedin regulatory update

...Janssen has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Oct 19, 2015
Clinical News

Yondelis trabectedin regulatory update

...alkaloid that binds the minor groove of DNA in Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Oct 12, 2015
Clinical News

Bamosiran: Phase II data

...a baseline IOP of >=25 mmHg. Bamosiran was well tolerated. Sylentis is a subsidiary of Zeltia S.A....
BioCentury | Oct 12, 2015
Clinical News

Yondelis trabectedin: Updated Phase III data

...unit has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Sep 28, 2015
Clinical News

Lurbinectedin: Phase II started

...Ewing’s family of tumors and carcinoma of unknown primary site. PharmaMar is a subsidiary of Zeltia S.A....
BioCentury | Sep 28, 2015
Clinical News

Yondelis trabectedin: Phase II started

...Johnson has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Sep 21, 2015
Clinical News

Yondelis trabectedin: Additional Phase II data

...unit has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
BioCentury | Jul 13, 2015
Clinical News

Lurbinectedin: Phase III started

...vs. pegylated liposomal doxorubicin or topotecan in about 420 patients. PharmaMar is a subsidiary of Zeltia S.A....
BioCentury | Jun 22, 2015
Clinical News

Lurbinectedin: Phase Ib data

...at the American Society of Clinical Oncology meeting in Chicago. PharmaMar is a subsidiary of Zeltia S.A....
BioCentury | Jun 22, 2015
Clinical News

Yondelis trabectedin: Interim Phase III data

...Janssen has rights to Yondelis outside of Europe and Japan from PharmaMar, a subsidiary of Zeltia S.A....
Items per page:
1 - 10 of 171